MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBCDerek A. Franklin, Justin M. Balko, Joe T. Sharick et al.|JCI Insight|2020Cited by 50
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Cindy Sander et al.|Clinical Cancer Research|2021Cited by 26
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell CarcinomaEileen Shiuan, Kathryn E. Beckermann, Anupama Reddy et al.|Cancers|2021Cited by 16
Abstract 6193: Exploring interplay between tumor intrinsic features and immune cell phenotypes in multi-tumor tissue microarrays by a single step 15-plex fluorescence immunohistochemistry and imaging on the Orion platformRichard Van Krieken, Jennifer Bordeaux, Jehovana O. Bender et al.|Cancer Research|2024Cited by 1
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0